The estimated Net Worth of Pavan Cheruvu is at least 2.99 百万$ dollars as of 8 July 2020. Pavan Cheruvu owns over 37,500 units of Axovant Gene Therapies stock worth over 121,456$ and over the last 7 years he sold AXGT stock worth over 0$. In addition, he makes 2,868,750$ as Chief Executive Officer、 Director at Axovant Gene Therapies.
Pavan has made over 2 trades of the Axovant Gene Therapies stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 37,500 units of AXGT stock worth 102,750$ on 8 July 2020.
The largest trade he's ever made was buying 37,500 units of Axovant Gene Therapies stock on 8 July 2020 worth over 102,750$. On average, Pavan trades about 5,625 units every 49 days since 2018. As of 8 July 2020 he still owns at least 57,836 units of Axovant Gene Therapies stock.
You can see the complete history of Pavan Cheruvu stock trades at the bottom of the page.
Dr. Pavan Cheruvu M.D. serves as Chief Executive Officer, Director of the Company. Dr. Cheruvu has served as our Principal Executive Officer and the Chief Executive Officer of Axovant Sciences, Inc. since February 2018 and as a member of the Board since September 2018. Prior to joining Axovant, Dr. Cheruvu worked at RSI since October 2015, and was appointed to RSI’s executive leadership team in September 2017. Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training in a clinical fellowship in cardiovascular medicine at the University of California, San Francisco. Prior to his medical training, Dr. Cheruvu worked as a management consultant at McKinsey & Company, a consulting company, from June 2008 through June 2011, where he focused on biopharmaceutical strategy. Dr. Cheruvu received his B.S.E. in Biomedical Engineering, B.S.E. in Electrical Engineering, and A.B. in Chemistry from Duke University, his M.Sc. in Computer Science from Oxford University and his M.D. from Harvard Medical School. Cheruvu’s experience as a life sciences investor and experience in the biopharmaceutical industry qualify him to serve on the Board.
As the Chief Executive Officer、 Director of Axovant Gene Therapies, the total compensation of Pavan Cheruvu at Axovant Gene Therapies is 2,868,750$. There are no executives at Axovant Gene Therapies getting paid more.
Pavan Cheruvu is 38, he's been the Chief Executive Officer、 Director of Axovant Gene Therapies since 2018. There are 7 older and 1 younger executives at Axovant Gene Therapies. The oldest executive at Axovant Gene Therapies Ltd. is Atul Pande, 66, who is the Lead Independent Director.
Pavan's mailing address filed with the SEC is 11 Times Square, New York, NY 10036, USA.
Over the last 6 years, insiders at Axovant Gene Therapies have traded over 0$ worth of Axovant Gene Therapies stock and bought 5,401,703 units worth 20,204,515$ . The most active insiders traders include Sciences Ltd. Roivant、Andrew Lo、Associates Gp Llcqvt Financ.... On average, Axovant Gene Therapies executives and independent directors trade stock every 65 days with the average trade being worth of 1,890,596$. The most recent stock trade was executed by Atul Pande on 8 July 2020, trading 10,000 units of AXGT stock currently worth 27,300$.
Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.
Axovant Gene Therapies executives and other stock owners filed with the SEC include: